Lantus, a new long-acting BASAL insulin
The FDA just approved Lantus, a new long-acting BASAL insulin.
It's longer acting than NPH or Ultralente...and doesn't produce peak concentrations like other insulins.
Lantus is a synthetic insulin called insulin glargine. It differs from human insulin by 3 amino acids.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote